WallStreetZenWallStreetZen

NASDAQ: BGNE
Beigene Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for BGNE

Based on 6 analysts offering 12 month price targets for Beigene Ltd.
Min Forecast
$196.00+2.84%
Avg Forecast
$275.17+44.38%
Max Forecast
$319.00+67.38%

Should I buy or sell BGNE stock?

Based on 6 analysts offering ratings for Beigene Ltd.
Strong Buy
Strong Buy
4 analysts 66.67%
Buy
1 analysts 16.67%
Hold
1 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BGNE stock forecasts and price targets.

BGNE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Citigroup
Bottom 4%
4
Strong BuyMaintains$290.00+52.17%2023-09-21
Bank of America
HoldMaintains$212.00+11.24%2023-09-20
Macquarie
Bottom 38%
38
BuyInitiates Coverage On$259.00+35.90%2023-09-12
Morgan Stanley
Bottom 3%
3
Strong BuyMaintains$319.00+67.38%2023-08-29
Jefferies
Bottom 21%
21
Strong BuyInitiates Coverage On$287.00+50.59%2023-08-17
JP Morgan
Bottom 46%
46
Strong BuyMaintains$300.00+57.41%2023-08-07
Bernstein
Bottom 35%
35
HoldDowngrades$196.00+2.84%2023-06-30

1 of 1

Forecast return on equity

Is BGNE forecast to generate an efficient return?
Company
N/A
Industry
0.91%
Market
28.82%

Forecast return on assets

Is BGNE forecast to generate an efficient return on assets?
Company
N/A
Industry
0.07%

BGNE revenue growth forecast

How is BGNE forecast to perform vs Biotechnology companies and vs the US market?
Company
28.49%
Industry
35.95%
Market
8.15%
BGNE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BGNE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BGNE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BGNE$190.58$275.17+44.38%Strong Buy
ALNY$171.55$254.10+48.12%Buy
GMAB$36.08$45.50+26.11%Buy
BMRN$86.51$115.44+33.44%Buy
RPRX$26.33$56.50+114.58%Strong Buy
View Top Biotech Stocks

Beigene Stock Forecast FAQ

Is Beigene Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: BGNE) stock is to Strong Buy BGNE stock.

Out of 6 analysts, 4 (66.67%) are recommending BGNE as a Strong Buy, 1 (16.67%) are recommending BGNE as a Buy, 1 (16.67%) are recommending BGNE as a Hold, 0 (0%) are recommending BGNE as a Sell, and 0 (0%) are recommending BGNE as a Strong Sell.

If you're new to stock investing, here's how to buy Beigene stock.

What is BGNE's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: BGNE) forecast ROE is N/A, which is considered weak.

What is BGNE's Price Target?

According to 6 Wall Street analysts that have issued a 1 year BGNE price target, the average BGNE price target is $275.17, with the highest BGNE stock price forecast at $319.00 and the lowest BGNE stock price forecast at $196.00.

On average, Wall Street analysts predict that Beigene's share price could reach $275.17 by Sep 21, 2024. The average Beigene stock price prediction forecasts a potential upside of 44.38% from the current BGNE share price of $190.58.

What is BGNE's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: BGNE) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.07%.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.